1. Kennecke, H., Yerushalmi, R., Woods, R., et al. (2010). Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology, 28, 3271-3277. doi: 10.1200/JCO.2009.25.9820.
  2. Laurent, E., Begueret, H., Bonhomme, B., et al. (2019). SOX10, GATA3, GCDFP15, androgen receptor, and mammoglobin for the differential diagnosis between triple-negative breast cancer and TTF1-negative lung adenocarcinoma. The American Journal of Surgical Pathology, 43(3), 293-302. doi: 10.1097/PAS.0000000000001216.
  3. Leslie, KO; Wick M. (2017). Metastatic tumors in the lung. In, Practical pulmonary pathology: a diagnostic approach (3rd ed., pp 621-638). Elsevier.
  4. Nelson, E., Sharma, R., Argani, P. Cimino-Mathews, A. (2017). Utility of SOX10 labeling in metastatic breast carcinomas. Human Pathology, 67, 205-210. doi: 10.1016/j.humpath.2017.08.011.
  5. Tozbikian, G., Zynger, D. (2018). A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Human Pathology, 85, 221-227. doi: 10.1016/j.humpath.2018.11.005
  6. Qi, J., Hu, Z., Xiao, H., et al. (2020). SOX10 – a novel marker for the differential diagnosis of breast metaplastic squamous cell carcinoma. Cancer Management and Research, 12, 4039-4044. doi: 10.2147/CMAR.S250867.